AXGT stock forecast
Our latest prediction for Axovant Gene Therapies Ltd.'s stock price was made on the June 14, 2019 when the stock price was at 5.12$.
In the short term (2weeks), AXGT's stock price should outperform the market by 6.31%. During that period the price should oscillate between -10.86% and +23.38%.
In the medium term (3months), AXGT's stock price should outperform the market by 1.74%. During that period the price should oscillate between -23.21% and +46.61%.Get email alerts
About Axovant Gene Therapies Ltd.
Axovant Gene Therapies Ltd. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of gene therapies for neurological diseases. Its product pipeline focus on Parkinson's Disease, GM1 gangliosidosis, and GM2 gangliosidosis such as Tay-Sachs disease and Sandhoff disease. The company was founded on October 31, 2014 and is headquartered in London, United Kingdom.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -8.02$ per share.
The book value per share is 2.47$
Three months stock forecastJune 14, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|